Abstract

Disruption to axonal transport is an early pathological feature in Alzheimer's disease. The amyloid precursor protein (APP) is a key axonal transport cargo in Alzheimer's disease since perturbation of its transport increases APP processing and production of amyloid-β peptide (Aβ) that is deposited in the brains of Alzheimer's disease patients. APP is transported anterogradely through axons on kinesin-1 motors. One favoured route for attachment of APP to kinesin-1 involves the scaffolding protein c-Jun N-terminal kinase-interacting protein-1 (JIP1), which has been shown to bind both APP and kinesin-1 light chain (KLC). However, direct experimental evidence to support a role of JIP1 in APP transport is lacking. Notably, the effect of loss of JIP1 on movement of APP through axons of living neurons, and the impact of such loss on APP processing and Aβ production has not been reported. To address these issues, we monitored how siRNA mediated loss of JIP1 influenced transport of enhanced green fluorescent protein (EGFP)-tagged APP through axons and production of endogenous Aβ in living neurons. Surprisingly, we found that knockdown of JIP1 did not affect either APP transport or Aβ production. These results have important implications for our understanding of APP trafficking in Alzheimer's disease.

Highlights

  • The correct transport of protein and organelle cargoes through axons is an essential requirement for proper functioning of neurons

  • Jun N-terminal kinase-interacting protein-1 (JIP1) is a ligand for kinesin-1 light chain (KLC) and via its PTB domain binds to the C-terminus of amyloid precursor protein (APP) (27,32,36 – 41)

  • JIP1 has been favoured as a scaffold to connect APP to KLC/kinesin-1 for anterograde axonal transport [27,32,35,36]

Read more

Summary

Introduction

The correct transport of protein and organelle cargoes through axons (axonal transport) is an essential requirement for proper functioning of neurons. Perturbation of axonal transport is known to contribute to the pathogenic process in some neurodegenerative diseases (see for reviews [1,2,3,4]). Altered metabolism of amyloid precursor protein (APP) leading to changes in production of amyloid-b peptide (Ab) is believed to be central to the disease process. Ab is an approximately 40– 42 amino acid peptide that is derived from APP by proteolytic processing and which is deposited in the brains of Alzheimer’s disease patients within amyloid plaques. APP is processed by a- and g-secretase but since a-secretase cleaves within the Ab sequence, this route precludes Ab production (see for review [5]). As such, understanding the mechanisms that control APP processing and Ab production has major relevance to Alzheimer’s disease research

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call